Literature DB >> 23851615

Roles of lipoxin A4 in preventing paracetamol-induced acute hepatic injury in a rabbit model.

Jian Xia1, Xian-Long Zhou, Yan Zhao, You-Qing Zhu, Shan Jiang, Shao-Zhou Ni.   

Abstract

The objective of this research is to investigate the potential role of lipoxin A4 in preventing paracetamol (PCM)-induced hepatic injury. One hundred male New Zealand white rabbits were randomly divided into control group, PCM group, N-acetylcysteine (NAC) group, lipoxin A4 (LXA4) group, and LXA4 + NAC group. The rabbits were assigned to receive 300 mg/kg weight PCM in 0.9 % saline or equivalent volume of saline via gastric lavage. LXA4 (1.5 μg/kg) and equivalent volume of 2 % ethanol were separately given to the rabbits in LXA4-treated and PCM groups 24 h after PCM administration. Meanwhile, the rabbits in the NAC-treated groups received a loading dose of 140 mg/kg of N-acetylcysteine. The blood samples and liver tissue were collected for biochemical and histological evaluation 36 h after paracetamol administration. The administration of LXA4 24 h after paracetamol poisoning resulted in significant improvement in hepatic injury as represented by decrease of hepatocellular enzyme release and attenuation of hepatocyte apoptosis and necrosis. In LXA4-treated groups, the expression of TNF-α was significantly lower than those in PCM and NAC groups (p < 0.05). In contrast, the level of IL-10 was significantly higher than PCM and NAC groups (p < 0.05). Moreover, the expressions of NF-κB p65 in PCM and NAC groups were significantly increased compared with those of LXA4-treated groups and control group (respectively, p < 0.05 and p < 0.01). LXA4-treated groups also showed significantly higher survival rates. Lipoxin A4 significantly mitigates paracetamol-induced hepatic injury, in which anti-inflammation effect may play an important role, leading to hepatic apoptosis and necrosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23851615     DOI: 10.1007/s10753-013-9683-2

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  30 in total

Review 1.  Active participation of endothelial cells in inflammation.

Authors:  Joan M Cook-Mills; Tracy L Deem
Journal:  J Leukoc Biol       Date:  2005-01-03       Impact factor: 4.962

2.  Diminished lipoxin biosynthesis in severe asthma.

Authors:  Bruce D Levy; Caroline Bonnans; Eric S Silverman; Lyle J Palmer; Gautham Marigowda; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2005-06-16       Impact factor: 21.405

Review 3.  Mechanisms of drug-induced liver disease.

Authors:  Basuki K Gunawan; Neil Kaplowitz
Journal:  Clin Liver Dis       Date:  2007-08       Impact factor: 6.126

4.  Oral N-acetyl-L-cysteine is a safe and effective precursor of cysteine.

Authors:  R N Dilger; D H Baker
Journal:  J Anim Sci       Date:  2007-03-19       Impact factor: 3.159

5.  15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure.

Authors:  Martin O Leonard; Kieran Hannan; Melissa J Burne; David W P Lappin; Peter Doran; Patrick Coleman; Catherine Stenson; Cormac T Taylor; Frank Daniels; Catherine Godson; Nicos A Petasis; Hamid Rabb; Hugh R Brady
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

Review 6.  Treating myocardial ischemia-reperfusion injury by targeting endothelial cell transcription.

Authors:  E M Boyle; T G Canty; E N Morgan; W Yun; T H Pohlman; E D Verrier
Journal:  Ann Thorac Surg       Date:  1999-11       Impact factor: 4.330

Review 7.  NF-κB, inflammation, and metabolic disease.

Authors:  Rebecca G Baker; Matthew S Hayden; Sankar Ghosh
Journal:  Cell Metab       Date:  2011-01-05       Impact factor: 27.287

Review 8.  Cellular and molecular mechanisms of liver injury.

Authors:  Harmeet Malhi; Gregory J Gores
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

9.  Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells.

Authors:  Nicole Baker; Sarah J O'Meara; Michael Scannell; Paola Maderna; Catherine Godson
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

Review 10.  Acetaminophen-induced hepatotoxicity.

Authors:  Laura P James; Philip R Mayeux; Jack A Hinson
Journal:  Drug Metab Dispos       Date:  2003-12       Impact factor: 3.922

View more
  3 in total

1.  Maresin 1, a Proresolving Lipid Mediator, Mitigates Carbon Tetrachloride-Induced Liver Injury in Mice.

Authors:  Ruidong Li; Yaxin Wang; Ende Zhao; Ke Wu; Wei Li; Liang Shi; Di Wang; Gengchen Xie; Yuping Yin; Meizhou Deng; Peng Zhang; Kaixiong Tao
Journal:  Oxid Med Cell Longev       Date:  2016-01-06       Impact factor: 6.543

2.  BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo.

Authors:  Yu-Dong Ji; Zhen-Long Luo; Chun-Xiu Chen; Bo Li; Jie Gong; Ya-Xin Wang; Lin Chen; Shang-Long Yao; You Shang
Journal:  Int J Mol Med       Date:  2018-10-02       Impact factor: 4.101

3.  Lipoxin A4 attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis.

Authors:  Qiong-Feng Chen; Xiao-Dong Kuang; Qi-Feng Yuan; Hua Hao; Ting Zhang; Yong-Hong Huang; Xiao-Yan Zhou
Journal:  Innate Immun       Date:  2018-07-03       Impact factor: 2.680

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.